These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

786 related items for PubMed ID: 16243831

  • 21. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [Abstract] [Full Text] [Related]

  • 22. Efficient CTL productivity of modified fusion cells by increase of heat shock protein 70.
    Koide T, Iinuma H, Fukushima R.
    Oncol Rep; 2009 Mar; 21(3):737-46. PubMed ID: 19212634
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM, Schlom J, Hodge JW.
    Cancer Res; 2002 Oct 15; 62(20):5770-7. PubMed ID: 12384537
    [Abstract] [Full Text] [Related]

  • 25. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo.
    Drexler I, Antunes E, Schmitz M, Wölfel T, Huber C, Erfle V, Rieber P, Theobald M, Sutter G.
    Cancer Res; 1999 Oct 01; 59(19):4955-63. PubMed ID: 10519409
    [Abstract] [Full Text] [Related]

  • 26. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L.
    Cancer Res; 2005 Jul 15; 65(14):6435-42. PubMed ID: 16024648
    [Abstract] [Full Text] [Related]

  • 27. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
    Saha A, Chatterjee SK.
    Scand J Immunol; 2010 Feb 15; 71(2):70-82. PubMed ID: 20384858
    [Abstract] [Full Text] [Related]

  • 28. HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy.
    Fauquembergue E, Toutirais O, Tougeron D, Drouet A, Le Gallo M, Desille M, Cabillic F, de La Pintière CT, Iero M, Rivoltini L, Baert-Desurmont S, Leprince J, Vaudry H, Sesboué R, Frébourg T, Latouche JB, Catros V.
    J Immunother; 2010 May 15; 33(4):402-13. PubMed ID: 20386466
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8(+) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells.
    Dai S, Zhou X, Wang B, Wang Q, Fu Y, Chen T, Wan T, Yu Y, Cao X.
    J Mol Med (Berl); 2006 Dec 15; 84(12):1067-76. PubMed ID: 17016692
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells.
    Ohta K, Yamaguchi Y, Shimizu K, Miyahara E, Toge T.
    Anticancer Res; 2002 Dec 15; 22(5):2597-606. PubMed ID: 12529970
    [Abstract] [Full Text] [Related]

  • 33. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
    Kudo-Saito C, Schlom J, Hodge JW.
    Clin Cancer Res; 2005 Mar 15; 11(6):2416-26. PubMed ID: 15788693
    [Abstract] [Full Text] [Related]

  • 34. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine.
    Zhu MZ, Marshall J, Cole D, Schlom J, Tsang KY.
    Clin Cancer Res; 2000 Jan 15; 6(1):24-33. PubMed ID: 10656428
    [Abstract] [Full Text] [Related]

  • 35. A combination of exosomes carrying TSA derived from HLA-A2-positive human white buffy coat and polyI:C for use as a subcellular antitumor vaccination.
    Ren WN, Chang CK, Fan HH, Guo F, Ren YN, Yang J, Guo J, Li X.
    J Immunoassay Immunochem; 2011 Jan 15; 32(3):207-18. PubMed ID: 21574092
    [Abstract] [Full Text] [Related]

  • 36. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
    McLaughlin JP, Schlom J, Kantor JA, Greiner JW.
    Cancer Res; 1996 May 15; 56(10):2361-7. PubMed ID: 8625312
    [Abstract] [Full Text] [Related]

  • 37. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes.
    Lu J, Celis E.
    Cancer Res; 2000 Sep 15; 60(18):5223-7. PubMed ID: 11016651
    [Abstract] [Full Text] [Related]

  • 38. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
    Motomura Y, Ikuta Y, Kuronuma T, Komori H, Ito M, Tsuchihara M, Tsunoda Y, Shirakawa H, Baba H, Nishimura Y, Kinoshita T, Nakatsura T.
    Int J Oncol; 2008 May 15; 32(5):985-90. PubMed ID: 18425324
    [Abstract] [Full Text] [Related]

  • 39. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
    Cesson V, Stirnemann K, Robert B, Luescher I, Filleron T, Corradin G, Mach JP, Donda A.
    Clin Cancer Res; 2006 Dec 15; 12(24):7422-30. PubMed ID: 17189415
    [Abstract] [Full Text] [Related]

  • 40. 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine.
    Correale P, Del Vecchio MT, Di Genova G, Savellini GG, La Placa M, Terrosi C, Vestri M, Urso R, Lemonnier F, Aquino A, Bonmassar E, Giorgi G, Francini G, Cusi MG.
    J Natl Cancer Inst; 2005 Oct 05; 97(19):1437-45. PubMed ID: 16204693
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.